Vitamin Shoppe Inc (NYSE:VSI) – Equities research analysts at Gabelli reduced their FY2017 earnings per share estimates for shares of Vitamin Shoppe in a report issued on Thursday. Gabelli analyst D. Witkowski now expects that the specialty retailer will earn $1.50 per share for the year, down from their previous estimate of $2.00. Gabelli currently has a “Hold” rating on the stock. Gabelli also issued estimates for Vitamin Shoppe’s FY2018 earnings at $1.65 EPS, FY2019 earnings at $1.95 EPS, FY2020 earnings at $2.10 EPS and FY2021 earnings at $2.25 EPS.

Vitamin Shoppe (NYSE:VSI) last posted its earnings results on Wednesday, May 10th. The specialty retailer reported $0.37 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $0.58 by $0.21. The business had revenue of $316.90 million for the quarter, compared to analyst estimates of $325.71 million. Vitamin Shoppe had a net margin of 3.34% and a return on equity of 11.52%. The business’s revenue was down 5.9% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.67 EPS. ILLEGAL ACTIVITY NOTICE: “Gabelli Weighs in on Vitamin Shoppe Inc’s FY2017 Earnings (VSI)” was published by American Banking News and is the property of of American Banking News. If you are reading this piece on another publication, it was copied illegally and republished in violation of U.S. & international trademark and copyright legislation. The legal version of this piece can be viewed at https://www.americanbankingnews.com/2017/05/15/gabelli-weighs-in-on-vitamin-shoppe-incs-fy2017-earnings-vsi.html.

Earnings History and Estimates for Vitamin Shoppe (NYSE:VSI)

VSI has been the subject of several other reports. Morgan Stanley downgraded shares of Vitamin Shoppe from an “equal weight” rating to an “underweight” rating and set a $22.00 price objective for the company. in a report on Tuesday, January 17th. Goldman Sachs Group Inc downgraded shares of Vitamin Shoppe from a “neutral” rating to a “sell” rating and set a $21.00 price objective for the company. in a report on Thursday, January 19th. Zacks Investment Research downgraded shares of Vitamin Shoppe from a “buy” rating to a “hold” rating in a report on Friday, January 20th. Finally, Barclays PLC reaffirmed an “equal weight” rating and set a $13.00 price objective (down from $24.00) on shares of Vitamin Shoppe in a report on Sunday. Two research analysts have rated the stock with a sell rating, seven have given a hold rating and one has issued a buy rating to the stock. The stock currently has an average rating of “Hold” and an average target price of $24.00.

Vitamin Shoppe (NYSE:VSI) opened at 12.65 on Monday. Vitamin Shoppe has a 12-month low of $11.90 and a 12-month high of $32.31. The firm has a market cap of $301.94 million, a price-to-earnings ratio of 16.28 and a beta of 0.59. The company’s 50 day moving average is $18.78 and its 200 day moving average is $21.99.

A number of hedge funds have recently modified their holdings of VSI. Geode Capital Management LLC increased its stake in shares of Vitamin Shoppe by 10.4% in the first quarter. Geode Capital Management LLC now owns 204,242 shares of the specialty retailer’s stock worth $4,114,000 after buying an additional 19,241 shares during the period. Vanguard Group Inc. increased its stake in shares of Vitamin Shoppe by 14.8% in the first quarter. Vanguard Group Inc. now owns 2,186,549 shares of the specialty retailer’s stock worth $44,059,000 after buying an additional 282,598 shares during the period. Menta Capital LLC increased its stake in shares of Vitamin Shoppe by 39.6% in the first quarter. Menta Capital LLC now owns 100,388 shares of the specialty retailer’s stock worth $2,023,000 after buying an additional 28,470 shares during the period. Marshall Wace North America L.P. bought a new stake in shares of Vitamin Shoppe during the first quarter worth $308,000. Finally, MARSHALL WACE ASIA Ltd bought a new stake in shares of Vitamin Shoppe during the first quarter worth $308,000.

In other Vitamin Shoppe news, Director B. Michael Becker sold 2,729 shares of the stock in a transaction on Wednesday, March 8th. The shares were sold at an average price of $19.41, for a total value of $52,969.89. Following the completion of the sale, the director now directly owns 2,279 shares of the company’s stock, valued at approximately $44,235.39. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director Richard L. Markee sold 100,000 shares of the stock in a transaction on Friday, March 3rd. The shares were sold at an average price of $22.24, for a total transaction of $2,224,000.00. Following the completion of the sale, the director now directly owns 160,990 shares of the company’s stock, valued at $3,580,417.60. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 108,161 shares of company stock valued at $2,398,429. 1.29% of the stock is owned by insiders.

Vitamin Shoppe Company Profile

Vitamin Shoppe, Inc (VSI) is a multi-channel specialty retailer and contract manufacturer of vitamins, minerals, herbs, specialty supplements, sports nutrition, and other health and wellness products. The Company operates through three segments: retail, direct and manufacturing. The retail segment includes Vitamin Shoppe, Super Supplements and Vitapath retail store formats.

5 Day Chart for NYSE:VSI

Receive News & Ratings for Vitamin Shoppe Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vitamin Shoppe Inc and related companies with MarketBeat.com's FREE daily email newsletter.